Raymond James Financial Services Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-116,267
| Closed | -$2.16M | – | 3471 |
|
|
2023
Q3 | $2.16M | Sell |
116,267
-78,085
| -40% | -$883K | ﹤0.01% | 1463 |
|
|
2023
Q2 | $2.15M | Buy |
194,352
+27,976
| +17% | +$390K | ﹤0.01% | 1469 |
|
|
2023
Q1 | $2.23M | Sell |
166,376
-3,501
| -2% | -$60.6K | ﹤0.01% | 1423 |
|
|
2022
Q4 | $2.1M | Sell |
169,877
-6,802
| -4% | -$96.3K | ﹤0.01% | 1414 |
|
|
2022
Q3 | $2.46M | Buy |
176,679
+23,611
| +15% | +$380K | 0.01% | 1316 |
|
|
2022
Q2 | $2.11M | Buy |
153,068
+2,355
| +2% | +$37.7K | ﹤0.01% | 1407 |
|
|
2022
Q1 | $2.45M | Sell |
150,713
-12,072
| -7% | -$189K | ﹤0.01% | 1376 |
|
|
2021
Q4 | $2.65M | Buy |
162,785
+11,474
| +8% | +$193K | ﹤0.01% | 1358 |
|
|
2021
Q3 | $2.25M | Buy |
151,311
+71,097
| +89% | +$1.14M | ﹤0.01% | 1426 |
|
|
2021
Q2 | $1.6M | Buy |
80,214
+8,398
| +12% | +$166K | ﹤0.01% | 1633 |
|
|
2021
Q1 | $1.66M | Buy |
71,816
+26,893
| +60% | +$750K | ﹤0.01% | 1510 |
|
|
2020
Q4 | $1.11M | Sell |
44,923
-8,074
| -15% | -$268K | ﹤0.01% | 1638 |
|
|
2020
Q3 | $2.2M | Sell |
52,997
-18,448
| -26% | -$848K | 0.01% | 1122 |
|
|
2020
Q2 | $3.42M | Buy |
71,445
+17,030
| +31% | +$1.32M | 0.01% | 870 |
|
|
2020
Q1 | $3.43M | Buy |
54,415
+51,101
| +1,542% | +$4.59M | 0.01% | 654 |
|
|
2019
Q4 | $411K | Sell |
3,314
-3,243
| -49% | -$290K | ﹤0.01% | 2101 |
|
|
2019
Q3 | $435K | Buy |
6,557
+3,575
| +120% | +$240K | ﹤0.01% | 1994 |
|
|
2019
Q2 | $237K | Sell |
2,982
-301
| -9% | -$26.9K | ﹤0.01% | 2425 |
|
|
2019
Q1 | $367K | Buy |
+3,283
| New | +$359K | ﹤0.01% | 2100 |
|
|
2018
Q4 | – | Sell |
-5,517
| Closed | -$697K | – | 2884 |
|
|
2018
Q3 | $697K | Buy |
+5,517
| New | +$584K | ﹤0.01% | 1683 |
|
Raymond James Financial Services Advisors's ICPT Position: Q4 2023 in Review
Raymond James Financial Services Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 116,267 shares — an estimated $2.16M sold.
Raymond James Financial Services Advisors first reported a position in ICPT in Q3 2018 and held it in 20 quarters. The position peaked at $3.43M in Q1 2020. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Raymond James Financial Services Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Raymond James Financial Services Advisors sold 116,267 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $2.16M.
- Raymond James Financial Services Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 20 quarters.
- Raymond James Financial Services Advisors's Intercept Pharmaceuticals, Inc. position peaked at $3.43M in Q1 2020.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.